Published in Blood on December 23, 2016
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv (2017) 0.75
Preparing Viable Single Cells from Human Tissue and Tumors for Cytomic Analysis. Curr Protoc Mol Biol (2017) 0.75
Drug modulators of B cell signaling pathways and Epstein-Barr virus lytic activation. J Virol (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell (1997) 7.18
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43
Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell (2004) 6.24
Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol (2008) 6.09
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell (2004) 4.31
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res (2009) 3.87
B cell antigen receptor signaling 101. Mol Immunol (2004) 3.58
Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol (2002) 3.27
Molecular components of the B-cell antigen receptor complex of the IgM class. Nature (1990) 3.06
ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol (2006) 2.63
Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol (2002) 2.37
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature (2012) 2.36
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2011) 2.11
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Mutations driving CLL and their evolution in progression and relapse. Nature (2015) 2.06
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins. J Immunol (2015) 2.00
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood (2002) 1.94
Regulation of an early developmental checkpoint in the B cell pathway by Ig beta. Science (1996) 1.88
Early events in B cell activation. Annu Rev Immunol (2010) 1.86
Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood (2002) 1.85
BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood (2008) 1.78
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer (2014) 1.76
Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol (2006) 1.72
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood (2013) 1.69
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell (2015) 1.67
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol (2015) 1.58
Syk and pTyr'd: Signaling through the B cell antigen receptor. Biochim Biophys Acta (2009) 1.55
Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood (2007) 1.55
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54
Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev (2009) 1.46
BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci U S A (2001) 1.32
Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci U S A (2010) 1.14
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood (2013) 1.12
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood (2014) 1.08
Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data. Methods (2015) 1.06
Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling. Immunol Rev (2009) 1.05
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood (2014) 1.01
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol (2014) 0.97
Beyond the age of cellular discovery. Nat Immunol (2014) 0.96
Self-antigen recognition by follicular lymphoma B-cell receptors. Blood (2012) 0.95
A practical approach to T-cell receptor cloning and expression. PLoS One (2011) 0.93
Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma. PLoS One (2012) 0.91
Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc Natl Acad Sci U S A (2015) 0.91
Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood (1997) 0.91
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood (2016) 0.82
Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol (2013) 0.81
Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica (1999) 0.81
IL-4 enhances expression and function of surface IgM in CLL cells. Blood (2016) 0.79
IgG1 cytoplasmic tail is essential for cell surface expression in Igβ down-regulated cells. Biochem Biophys Res Commun (2014) 0.77
IL-4 rescues surface IgM expression in chronic lymphocytic leukemia. Blood (2016) 0.76
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients. Br J Haematol (2012) 0.76
Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors. Leukemia (2015) 0.76